2025
Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata
Ayoade O, Canavan M, Zolfaghari E, Caturegli G, Kim S, Boffa D. Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata. JTO Clinical And Research Reports 2025, 6: 100798. DOI: 10.1016/j.jtocrr.2025.100798.Peer-Reviewed Original ResearchNon-small cell lung cancerStage IV non-small cell lung cancerIV non-small cell lung cancerStage IV NSCLC patientsIV NSCLC patientsCell lung cancerMedian survivalNSCLC patientsLung cancerNon-small cell lung cancer patientsNational Cancer DatabaseKaplan Meier methodTwo-year survivalStratified Cox analysisAdjusted mortality riskMeier methodCancer DatabaseCox analysisEra 1NSCLC treatmentSurvival gainChemotherapy administrationNon-Hispanic blacksPatientsHispanic patients
2024
Applying Language Models to Radiology Text for Identifying Oligometastatic Non-Small Cell Lung Cancer
Moore N, Laird J, Verma N, Hager T, Sritharan D, Lee V, Maresca R, Chadha S, Park H, Aneja S. Applying Language Models to Radiology Text for Identifying Oligometastatic Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e644. DOI: 10.1016/j.ijrobp.2024.07.1417.Peer-Reviewed Original ResearchNon-small cell lung cancerOligometastatic diseaseCell lung cancerRadiologic impressionTumor RegistryTest cohortOligometastatic non-small cell lung cancerIV non-small cell lung cancerStage IV non-small cell lung cancerLung cancerConvolutional neural networkMetastasis-directed therapyOligometastatic NSCLC patientsMonths of diagnosisLanguage modelClinician reviewNSCLC patientsPatient cohortClinical dataScreening patientsSubgroup analysisBrain MRIClinical textBurden of diseaseClinical relevanceImmunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes D, Frey A, Prsic E, Tran T, Clune J, Sznol M, Kluger H, Forman H, Becher R, Olino K, Khan S. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncology 2024, 10: 342-351. PMID: 38175659, PMCID: PMC10767643, DOI: 10.1001/jamaoncol.2023.6025.Peer-Reviewed Original ResearchNon-small cell lung cancerEnd of lifeMonth of deathImmunotherapy initiationCohort studyMAIN OUTCOMEStage IV non-small cell lung cancerCharlson-Deyo comorbidity indexHigh metastatic burdenInitiation of immunotherapyNational prescribing patternsRisk-adjusted patientsImmune checkpoint inhibitorsRetrospective cohort studyStage IV melanomaPercentage of patientsHigh-volume centersLocation of metastasesLow-volume centersOdds of deathCell lung cancerNational Clinical DatabaseLow-volume facilitiesDrug Administration approvalCheckpoint inhibitors
2022
OA11.03 Nonregional Lymph Nodes as the Only Metastatic Site in Stage IV Non-Small Cell Lung Cancer: A Marker of Better Prognosis
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Kaminski M, Boffa D. OA11.03 Nonregional Lymph Nodes as the Only Metastatic Site in Stage IV Non-Small Cell Lung Cancer: A Marker of Better Prognosis. Journal Of Thoracic Oncology 2022, 17: s29-s30. DOI: 10.1016/j.jtho.2022.07.056.Peer-Reviewed Original ResearchAssociation Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US
Ermer T, Canavan ME, Maduka RC, Li AX, Salazar MC, Kaminski MF, Pichert MD, Zhan PL, Mase V, Kluger H, Boffa DJ. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US. JAMA Network Open 2022, 5: e2219535. PMID: 35771575, PMCID: PMC9247736, DOI: 10.1001/jamanetworkopen.2022.19535.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerRenal cell carcinomaUse of immunotherapyFDA approvalImmunotherapy useCohort studyClinical trialsNovel therapiesStage IV non-small cell lung cancerMultivariable logistic regression modelingFirst checkpoint inhibitorCheckpoint inhibitor therapyNational Cancer DatabasePatients 20 yearsCell lung cancerSocioeconomic strataTreatment of patientsDrug Administration approvalLife-saving treatmentReceipt of immunotherapyLogistic regression modelingSocioeconomic characteristicsImmunotherapy administrationCheckpoint inhibitorsPatient characteristicsImplications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies
Brown S, Lavery J, Shen R, Martin A, Kehl K, Sweeney S, Lepisto E, Rizvi H, McCarthy C, Schultz N, Warner J, Park B, Bedard P, Riely G, Schrag D, Panageas K, Sweeney S, Foti M, Khotskaya Y, Fiandalo M, Gross B, Schultz N, Mastrogiacomo B, Sarmardy M, Li M, Resnick A, Waanders A, Lilly J, Carvajal R, Rabadan R, Ingham M, Hsaio S, Abraham J, Brenton J, Rueda O, Caldas C, Valgañón M, Silva D, Boursnell C, Garcia R, Rodriguez E, Nimmervoll B, Cerami E, Ducar M, Kumari P, Lindeman N, MacConnaill L, Orechia J, Schrag D, Shivdasani P, Van Allen E, Johnson J, Jänne P, Lepisto E, Hassett M, Pimentel S, Sripakdeevong P, Janeway K, Johnson J, Meyerson M, Quinn D, Cushing O, Haigis K, Miller D, Kehl K, Gustav A, Tramontano A, Baquero S, Bell J, Green M, McCall S, Datto M, Calvo F, Andre F, Guillaume M, Dogan S, Ludovic L, Scoazec J, Ardenos M, Vassal G, Michels S, Velculescu V, Baras A, Gocke C, Brahmer J, Sawyers C, Solit D, Gardos S, Berger M, Ladanyi M, Riely G, Sirintrapun J, Panageas K, Caroline A, Thomas S, Zarski A, Zehir A, Iasonosa A, Philip J, Brown S, Kung A, Kundra R, Rudolph J, Lavery J, Rivzi H, Schwartz J, McCarthy C, Bhuiya M, Martin A, Chu C, DuBois R, van de Velde T, Meijer G, Horlings H, van Tinteren H, Lolkema M, Nijman L, Bierkens M, Hoeve J, Voest E, Hiemstra A, Sonke G, Craenmehr J, Hudecek J, Monkhorst K, Urba W, Bernard B, Piening B, Bifulco C, Tittel P, Cramer J, Guinney J, Yu T, Guo X, Acebedo A, Gold P, Bailey N, Kadri S, Segal J, Pankhuri W, Wang P, George S, Christine M, Van't Veer L, Talevich E, Wren A, Sweet-Cordero A, Turski M, Bedard P, KamelReid S, Lu Z, Pugh T, Siu L, Watt S, Leighl N, Yu C, Ahmed L, Krishna G, Virtaenen C, Chow H, Plagianakos D, Del Rossi S, Singaravelan N, Hakgor S, Qazi N, Nguyen A, Stickle N, Stricker T, Micheel C, Anderson I, Jones L, Wang L, Lovly C, LeNoue Newton M, Park B, Warner J, Fabbri D, Coco J, Ye C, Chaugai S, Mishra S, Yang Y, Wen L, Dienstmann R, Aguilar Izquierdo S, Viaplana Donato C, Mancuso F, Topaloglu U, Liu L, Guan M, Zhang W, Jin G, Knight J, D'Eletto M, Ormay E, Mane S, Bilguvar K, Zenta W, Dykas D. Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies. JAMA Oncology 2022, 8: 287-291. PMID: 34734967, PMCID: PMC9190030, DOI: 10.1001/jamaoncol.2021.5153.Peer-Reviewed Original ResearchConceptsOverall survivalStage IV non-small cell lung cancerNon-small cell lung cancerStage IV colorectal cancerUnadjusted median survivalCell lung cancerMedian survivalStudy entryCancer outcomesColorectal cancerLung cancerMolecular testingSurvival analysisGeneralizable research findingsClinical genomic studiesSurvivalCancerSelection biasAppropriate statistical methodsDiagnosisAmerican Association
2021
A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
Herbst R, Jassem J, Abogunrin S, James D, McCool R, Belleli R, Giaccone G, De Marinis F. A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression. Frontiers In Oncology 2021, 11: 676732. PMID: 34307144, PMCID: PMC8300186, DOI: 10.3389/fonc.2021.676732.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalObjective response rateStage IV non-small cell lung cancerFirst-line treatmentOverall survivalCell lung cancerLung cancerHigh Programmed-Death Ligand 1 (PD-L1) expressionMetastatic non-small cell lung cancerStage non-small cell lung cancerProgrammed Death Ligand 1 ExpressionTreatment-related adverse eventsDeath ligand 1 (PD-L1) expressionPD-L1 expressionPD-L1 statusAbsence of headNetwork Meta-AnalysisRisk of biasRandom-effects modelVersus ChemotherapyImmunotherapy regimenAdverse eventsHead trialsCombination regimensA phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).
Riess J, Redman M, Wheatley-Price P, Faller B, Villaruz L, Corum L, Gowda A, Srkalovic G, Osarogiagbon R, Baumgart M, Qian L, Minichiello K, Gandara D, Herbst R, Kelly K. A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A). Journal Of Clinical Oncology 2021, 39: 9024-9024. DOI: 10.1200/jco.2021.39.15_suppl.9024.Peer-Reviewed Original ResearchHomologous recombination deficiencyBRCA1/2 mutationsPARP inhibitorsAdverse eventsSystemic therapyStage IV non-small cell lung cancerNon-small cell lung cancerAdequate organ functionFrequent adverse eventsZubrod performance statusAdvanced NSCLC patientsNew safety signalsPhase II studyStage IV diseaseAdvanced-stage NSCLCCell lung cancerPhenotypic markersBRCA1/BRCA2Day of registrationEligible patientsEligible ptsMedian OSMedian PFSNSCLC ptsHematologic toxicity
2020
Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies.
Parikh R, Cohen R, Min E, Wileyto E, Riaz F, Gross C, Long Q, Mamtani R. Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies. Journal Of Clinical Oncology 2020, 38: e19316-e19316. DOI: 10.1200/jco.2020.38.15_suppl.e19316.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced solid malignanciesEastern Cooperative Oncology Group performance statusUrothelial cell carcinomaRenal cell carcinomaNon-frail patientsFrail patientsSolid malignanciesHepatocellular carcinomaCell carcinomaFlatiron Health electronic health record-derived databaseStage IV non-small cell lung cancerElectronic health record-derived databaseFirst-line immune checkpoint inhibitorsFirst-line ICI treatmentFirst-line systemic therapyImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitorsRetrospective cohort studyFirst-line useElixhauser Comorbidity IndexCell lung cancerMultivariable logistic regressionYears of treatment
2019
Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer
Uhlig J, Case MD, Blasberg JD, Boffa DJ, Chiang A, Gettinger SN, Kim HS. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e199702. PMID: 31433481, PMCID: PMC6707019, DOI: 10.1001/jamanetworkopen.2019.9702.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdolescentAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantComparative Effectiveness ResearchDatabases, FactualFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPneumonectomyProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSurvival RateTreatment OutcomeYoung AdultConceptsStage IV non-small cell lung cancerNon-small cell lung cancerPrimary tumor siteSuperior overall survivalSystemic therapySurgical resectionCell lung cancerExternal beam radiotherapyOverall survivalSurvival benefitLocal treatmentTumor siteTumor characteristicsLung cancerTreatment groupsMultivariable Cox proportional hazards regression modelsOligometastatic non-small cell lung cancerStage IV squamous cell carcinomaSurvival rateCox proportional hazards regression modelProportional hazards regression modelsComparative effectiveness research studyCancer-specific factorsNational Cancer DatabaseStage IV diseaseBenefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database.
Dendy Case M, Uhlig J, Blasberg J, Boffa D, Chiang A, Gettinger S, Kim H. Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database. Journal Of Clinical Oncology 2019, 37: 8545-8545. DOI: 10.1200/jco.2019.37.15_suppl.8545.Peer-Reviewed Original ResearchNon-small cell lung cancerNational Cancer DatabaseStage IV non-small cell lung cancerStage IV NSCLC patientsSystemic therapyOverall survivalSurgical resectionPatient demographicsNSCLC patientsCancer DatabaseMultivariable Cox proportional hazards modelsSquamous cell carcinoma patientsPropensity scoreMultivariable logistic regression modelCox proportional hazards modelSuperior overall survivalCell carcinoma patientsCell lung cancerLung cancer treatmentProportional hazards modelLogistic regression modelsLimited nodalTA patientsMetastatic diseaseMultivariable adjustmentClinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer
Aggarwal C, Thompson J, Black T, Katz S, Fan R, Yee S, Chien A, Evans T, Bauml J, Alley E, Ciunci C, Berman A, Cohen R, Lieberman D, Majmundar K, Savitch S, Morrissette J, Hwang W, Elenitoba-Johnson K, Langer C, Carpenter E. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer. JAMA Oncology 2019, 5: 173-180. PMID: 30325992, PMCID: PMC6396811, DOI: 10.1001/jamaoncol.2018.4305.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Non-Small-Cell LungClinical Decision-MakingDNA Mutational AnalysisFemaleGenetic Predisposition to DiseaseHumansLung NeoplasmsMaleMiddle AgedMutationPatient SelectionPhenotypePrecision MedicinePredictive Value of TestsPrognosisProspective StudiesConceptsNon-small cell lung cancerTissue next-generation sequencingMetastatic non-small cell lung cancerCell lung cancerTargetable mutationsNext-generation sequencingLung cancerPlasma testingStage IV non-small cell lung cancerAllele fractionNGS testingClinical implicationsPlasma next-generation sequencingPersonalized therapyReal-world clinical settingProspective cohort studyResponse Evaluation CriteriaRoutine clinical managementNumber of patientsSolid Tumors responseDNA next-generation sequencingStable diseaseMutation allele fractionCohort studyPartial response
2015
Outpatient palliative care encounters in stage IV lung cancer care: An institutional review.
Rizk S, Prsic E, Rafelson W, Reagan J, Taber A. Outpatient palliative care encounters in stage IV lung cancer care: An institutional review. Journal Of Clinical Oncology 2015, 33: 128-128. DOI: 10.1200/jco.2015.33.29_suppl.128.Peer-Reviewed Original ResearchNon-small cell lung cancerStandard oncologic careStage IV non-small cell lung cancerPalliative carePC interventionsOverall survivalSick visitsRetrospective analysisPC groupLung cancer carePalliative care encountersUtilization of emergencyLines of chemotherapyOutpatient palliative careReceipt of chemotherapyEmergency department visitsCell lung cancerCommon practice patternsStudy inclusion criteriaSignificant differencesPC encountersHospice referralDepartment visitsMultidisciplinary clinicOncologic care
2013
Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Socinski MA, Evans T, Gettinger S, Hensing TA, Sequist L, Ireland B, Stinchcombe TE. Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST Journal 2013, 143: e341s-e368s. PMID: 23649446, PMCID: PMC4694611, DOI: 10.1378/chest.12-2361.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Non-Small-Cell LungCetuximabErlotinib HydrochlorideGlutamatesGuanineHumansLung NeoplasmsNeoplasm StagingPatient SelectionPemetrexedPlatinum CompoundsProtein Kinase InhibitorsQuinazolinesConceptsStage IV non-small cell lung cancerNon-small cell lung cancerFirst-line therapyPerformance statusNonsquamous histologyLung cancerAmerican CollegeChest Physicians Evidence-Based Clinical Practice GuidelinesEastern Cooperative Oncology Group (ECOG) PSChest Physicians Lung Cancer GuidelinesEvidence-based clinical practice guidelinesNon-small cell lung cancer diagnosisEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsCell lung cancer diagnosisReceptor tyrosine kinase inhibitorsClinical patient characteristicsLung cancer guidelinesRole of cetuximabSafety of bevacizumabThird-line settingECOG performance statusGood performance statusPlatinum-based regimensPoor performance status
2012
Predictors of early discontinuation of chemotherapy (EDC) in patients (pts) age 65 or older with stage IV non-small cell lung cancer (NSCLC).
Gajra A, Tew W, Hardt M, Mohile S, Owusu C, Klepin H, Gross C, Lichtman S, Katheria V, Hurria A. Predictors of early discontinuation of chemotherapy (EDC) in patients (pts) age 65 or older with stage IV non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2012, 30: e18133-e18133. DOI: 10.1200/jco.2012.30.15_suppl.e18133.Peer-Reviewed Original ResearchStage IV non-small cell lung cancerNon-small cell lung cancerPoor physical functionOlder ptsPhysical functionAge 65Multi-site prospective studyBivariate analysisGeriatric assessment variablesPatients age 65Cell lung cancerMultivariate logistic regressionLower mean HbPt ageChemotherapy toxicityEarly discontinuationAlbumin levelsMean HbProspective studyPoor outcomeHigher cancerLung cancerPhysical scoresSubset analysisDisease progression
2009
A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status
Sequist L, Gettinger S, Natale R, Martins R, Lilenbaum R, Jänne P, Gray J, Samuel T, Grayzel D, Lynch T. A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. Journal Of Clinical Oncology 2009, 27: 8073-8073. DOI: 10.1200/jco.2009.27.15_suppl.8073.Peer-Reviewed Original ResearchNon-small cell lung cancerPhase II trialIPI-504Anti-tumor activityStable diseaseStage IIIBII trialPartial responseStage IV non-small cell lung cancerAdvanced non-small cell lung cancerCommon related adverse eventsIndependent radiology reviewAntitumor activityRelated adverse eventsCell lung cancerEGFR mutation analysisEGFR mutation statusHeat shock protein 90 inhibitorNSCLC cell linesShock protein 90 inhibitorsMurine xenograft modelCohort expansionEligible patientsNovel Hsp90 inhibitorPrior therapy
2001
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer
Kim E, Lu C, Khuri F, Tonda M, Glisson B, Liu D, Jung M, Hong W, Herbst R. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 2001, 34: 427-432. PMID: 11714540, DOI: 10.1016/s0169-5002(01)00278-1.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPhase II studyPlatinum-based chemotherapyCell lung cancerII studyLung cancerStage IV non-small cell lung cancerAdvanced non-small cell lung cancerGrade 3 nonhematological toxicitiesMedian Karnofsky performance statusPrior platinum-based chemotherapyPhase ICisplatin-based regimensPrior chemotherapy regimensGrade 4 toxicityKarnofsky performance statusPopulation of patientsDose-related toxicityNonhematological toxicitiesStable diseaseChemotherapy regimensRenal insufficiencyStage IIIBMedian survivalPerformance status
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply